INNOGEN-B (02591) announced that on August 25, 2025, the company has completed the first patient dosing in its Phase II clinical trial of Isupaglutide Alpha for the treatment of obesity and overweight in Australia. The company expects approximately 200 participants to be enrolled in this clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.